GUD vs. ACB, OGI, CPH, CRDL, HLS, WEED, CRON, TLRY, EXE, and FRX
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Aurora Cannabis (ACB), Organigram (OGI), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Canopy Growth (WEED), Cronos Group (CRON), Tilray Brands (TLRY), Extendicare (EXE), and Fennec Pharmaceuticals (FRX). These companies are all part of the "medical" sector.
Knight Therapeutics (TSE:GUD) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
Knight Therapeutics presently has a consensus target price of C$6.63, suggesting a potential upside of 13.97%. Aurora Cannabis has a consensus target price of C$2.26, suggesting a potential downside of 76.78%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Knight Therapeutics is more favorable than Aurora Cannabis.
13.7% of Knight Therapeutics shares are held by institutional investors. Comparatively, 7.0% of Aurora Cannabis shares are held by institutional investors. 46.5% of Knight Therapeutics shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aurora Cannabis has a net margin of 151.71% compared to Knight Therapeutics' net margin of -5.13%. Knight Therapeutics' return on equity of -2.14% beat Aurora Cannabis' return on equity.
In the previous week, Aurora Cannabis had 5 more articles in the media than Knight Therapeutics. MarketBeat recorded 7 mentions for Aurora Cannabis and 2 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.80 beat Aurora Cannabis' score of 0.24 indicating that Knight Therapeutics is being referred to more favorably in the media.
Aurora Cannabis has lower revenue, but higher earnings than Knight Therapeutics. Knight Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis received 418 more outperform votes than Knight Therapeutics when rated by MarketBeat users. However, 74.83% of users gave Knight Therapeutics an outperform vote while only 63.16% of users gave Aurora Cannabis an outperform vote.
Knight Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.83, indicating that its stock price is 183% more volatile than the S&P 500.
Summary
Knight Therapeutics beats Aurora Cannabis on 11 of the 18 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
